Qualcomm, AI and NVIDIA
Digest more
Over the past decade, Qualcomm has provided a significant $87 Bil back to its investors through tangible cash in the form of dividends and buybacks.
1hon MSN
Amazon layoffs, Qualcomm's AI chips, Airbnb cracks down on Halloween and more in Morning Squawk
Amazon CEO Andy Jassy said earlier this year that the Washington-based company could shrink its workforce by embracing AI. The firm is part of a cohort of large-cap companies that have seen their AI-related productivity increase as the technology becomes mainstream.
I strongly believe the October 27 launch of AI200/AI250 rack-scale inference systems is the inflection point, putting an AI stamp on Qualcomm and
Qualcomm entered the datacenter AI chip market with 2026-2027 products and a $1 billion Saudi deal despite specs trailing competitors.
CNBC’s Sara Eisen and Qualcomm CEO Cristiano Amon join 'Squawk Box' to discuss the release of its new AI accelerator chips, partnership with Saudi Arabia’s Humain, state of the AI chip race, and more.
Qualcomm's (NASDAQ:QCOM) push to enter the artificial intelligence accelerator market is a “meaningful diversification” for the San Diego-based chipmaker, Bank of America said. Read for more.
These are Qualcomm's next-generation AI inference-optimized solutions for data centers, and they bring with them support for gobs of memory.
The stock of Albemarle, one of the largest Lithium producers in the world, fell 8.9% after it announced its plan to sell a controlling stake in Ketjen Corporation’s refining catalyst solutions business to private equity firm KPS Capital Partners.
Investing.com - Qualcomm shares were lower in premarket U.S. trading on Tuesday, after the stock surged by over 11% in the prior session on the chipmaker’s unveiling of two new inference-optimized chips designed for data center artificial intelligence.
Qualcomm’s new AI accelerators compete with systems from Nvidia and Advanced Micro Devices. Both stocks were unmoved by Qualcomm’s announcement, with each closing up nearly 3% on the day. U.S.-listed shares of Novartis declined 2.8% after third-quarter earnings from the Swiss drugmaker disappointed.
Feedback